<DOC>
	<DOCNO>NCT02820519</DOCNO>
	<brief_summary>Loxapine antipsychotic drug approve treatment schizophrenia several country include United States . In animal study mice , loxapine reduce neuropathic pain . Hence , proof-of-principle dose-escalating study tolerability analgesic efficacy loxapine evaluate patient neuropathic pain .</brief_summary>
	<brief_title>Tolerability Analgesic Efficacy Loxapine Patients With Refractory , Chemotherapy-induced Neuropathic Pain</brief_title>
	<detailed_description>In dose-escalating study , 12 patient refractory , chemotherapy-induced neuropathic pain ( include mixed pain ) receive loxapine four 14-days treatment episode . The dosage episode 1 ( Days 1-14 ) 10 mg b.i.d. , dosages episode 2 , 3 , 4 define take account tolerability analgesic efficacy former episode . In case acceptable tolerability clinically relevant analgesic efficacy reach , loxapine dosage increase ( 2nd Episode 10 mg t.i.d , 3rd Episode 20 mg b.i.d. , 4th episode 20 mg t.i.d. ) . In case acceptable tolerability clinically relevant analgesic efficacy reach , loxapine dosage change . If clinically relevant ( serious ) adverse event ( ( S ) AEs ) occur , loxapine dosage reduce treatment interrupt stop irrespective analgesic efficacy . A clinically relevant pain reduction / analgesic efficacy define least 30 % decrease absolute decrease two scale unit compare baseline use 11-point numeric pain rating scale . Patients receive loxapine add-on treatment usual ( analgesic ) care .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Loxapine</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<criteria>Primarily chemotherapyinduced neuropathic pain ( include mixed pain ) least 3 month refractory least one analgesic compound Neuropathic pain &gt; = 4 ( 11point numeric pain scale ) screen visit ( include mixed pain ) Age &gt; = 18 year Body weight 50 150 kg Given write informed consent Participation interventional clinical study ( currently within last 3 month ) Parkinson 's disease , movement disorder ( extrapyramidal sign symptom ) associate antipsychotic , neuroleptic malignant syndrome , syndromes associate antipsychotic Severe hypotension syncope history , glaucoma , urinary retention , epilepsy seizure disorder history , severe dementia , dementiarelated psychosis history , malignancy life expectancy le 6 month , breast cancer history , lifethreatening condition Corrected QT interval ( QTc ) &gt; 460 m ( female ) &gt; 450 m ( male ) Known alcohol and/or drug abuse Concomitant intake antipsychotic , dopamine agonist ( Levodopa , bromocriptine , lisuride , pergolide , ropinirole , cabergoline , pramipexole , apomorphine ) , alphareceptor block compound Compounds strong evidence clinically relevant QT interval prolongation torsade de pointes risk increase Strong inhibitor CYP1A2 , CYP2D6 , CYP3A4 Known CYP2D6 Poor metabolizer status Pregnancy lactation period Missing insufficient contraception pre perimenopausal woman Close Affiliation investigational site</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Neuropathic pain</keyword>
	<keyword>Loxapine</keyword>
	<keyword>Antipsychotics</keyword>
	<keyword>Co-Analgesics</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Analgesic efficacy</keyword>
</DOC>